Septerna – Talk Bio

Novo Nordisk and Septerna Forge $2.2B+ Collaboration on Oral Obesity and Diabetes Drugs

3 weeks ago talkbio0Tagged cardiometabolic diseases, Collaboration, Diabetes Mellitus, Non-Insulin-Dependent, G-Protein-Coupled Receptors, Gastric Inhibitory Polypeptide, Glucagon Receptor, Glucagon-Like Peptide 1, Nordisk, Obesity, oral drugs, Septerna, small molecule therapies

Novo Nordisk; Septerna; GPCR; oral drugs; obesity; type 2 diabetes; cardiometabolic diseases; GLP-1; GIP; glucagon receptors; small molecule therapies; collaboration; pharmaceuticals

Septerna Halts Phase 1 Trial of SEP-786 Due to Unexpected Bilirubin Elevations

4 months ago talkbio0Tagged Agonist, Bilirubin, Clinical Trials, Discontinuation (procedure), Hypoparathyroidism, PTH1R gene, SEP-786, Septerna

Septerna, SEP-786, clinical trial discontinuation, hypoparathyroidism, bilirubin elevation, PTH1R agonist, biotech setback

Septerna Embarks on IPO Journey with Promising Preclinical Data and Vision to Revolutionize GPCR Drug Discovery

8 months ago talkbio0Tagged agonists, Biotechnology, Drug Discovery, G-Protein-Coupled Receptors, Hypoparathyroidism, IPO, Preclinical, PTH1R gene, Septerna

Septerna, IPO, GPCR, preclinical data, drug discovery, biotechnology, PTH1R agonists, hypoparathyroidism